Piramal Pharma Limited
HDFC Mutual Fund decreased its stake in Piramal Pharma Limited from 9.37% to 7.68%, selling 22,260,933 shares worth ₹386.58 Cr at ₹173.63 apiece.
A pharmaceutical company operating across three major segments: contract development and manufacturing organisations, complex hospital generics for critical care, and consumer healthcare products. Established through the acquisition of Nicholas Laboratories in 1988, the company has expanded via strategic mergers and acquisitions alongside organic growth initiatives. It serves healthcare providers and consumers across India through its diversified business operations and specialized pharmaceutical solutions.
One of India's oldest and most trusted AMCs with over Rs 7.5 lakh crore in AUM. Founded in 1999 as a joint venture between HDFC Bank and Standard Life. MD and CEO Navneet Munot, formerly CIO of SBI MF, has reinforced the quality and compounding philosophy across equity schemes. HDFC Flexi Cap Fund and HDFC Mid-Cap Opportunities Fund are among the largest actively managed equity schemes in India.